Fol. Biol. 2008, 54, 157-161
https://doi.org/10.14712/fb2008054050157
Lack of B-RAF Mutations in Head and Neck Squamous Cell Carcinoma
References
1. 2003) An intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer. J. Clin. Oncol. 21, 92-98.
< , D. J., Li, Y., Adams, G.. L., Wagner, H. Jr., Kish, J. A., Ensley, J. F., Schuller, D. E., Forastiere, A. A. (https://doi.org/10.1200/JCO.2003.01.008>
2. 2008) Expression and mutation analysis of epidermal growth factor receptor in head and neck squamous cell carcinoma. Cancer Sci. 99, 1589-1594.
, M., Gunduz, M., Nagatsuka, H., Gunduz, E., Cengiz, B., Fukushima, K., Beder, L. B., Demircan, K., Fujii, M., Yamanaka, N., Shimizu, K., Grenman, R., Nagai, N. (
3. 2007) Treatment of recurrent squamous cell carcinoma of the skin with cetuximab. Arch. Dermatol. 143, 889-892.
< , J. E., Eaton, K. D., Martins, R. G. (https://doi.org/10.1001/archderm.143.7.889>
4. 2006) Increased epidermal growth factor receptor gene copy number is associated with poor prognosis in head and neck squamous cell carcinomas. J. Clin. Oncol. 24, 4170-4176.
< , C. H., Ely, K., McGavran, L., Varella-Garcia, M., Parker, J., Parker, N., Jarrett, C., Carter, J., Murphy, B. A., Netterville, J., Burkey, B. B., Sinard, R., Cmelak, A., Levy, S., Yarbrough, W. G., Slebos, R. J., Hirsch, F. R. (https://doi.org/10.1200/JCO.2006.07.2587>
5. 2003) Phase II trial of ZD1839 in recurrent or metastatic squamous cell carcinoma of the head and neck. J. Clin. Oncol. 21, 1980-1987.
< , E. E., Rosen, F., Stadler, W. M., Recant, W., Stenson, K., Huo, D., Vokes, E. E. (https://doi.org/10.1200/JCO.2003.10.051>
6. 2002) Mutations of the BRAF gene in human cancer. Nature 417, 949-954.
< , H., Bignell, G. R., Cox, C., Stephens, P., Edkins, S., Clegg, S., Teague, J., Woffendin, H., Garnett, M. J., Bottomley, W., Davis, N., Dicks, E., Ewing, R., Floyd, Y., Gray, K., Hall, S., Hawes, R., Hughes, J., Kosmidou, V., Menzies, A., Mould, C., Parker, A., Stevens, C., Watt, S., Hooper, S., Wilson, R., Jayatilake, H., Gusterson, B. A., Cooper, C., Shipley, J., Hargrave, D., Pritchard-Jones, K., Maitland, N., Chenevix-Trench, G., Riggins, G.. J., Bigner, D. D., Palmieri, G., Cossu, A., Flanagan, A., Nicholson, A., Ho, J. W., Leung, S. Y., Yuen, S. T., Weber, B. L., Seigler, H. F., Darrow, T. L., Paterson, H., Marais, R., Marshall, C. J., Wooster, R., Stratton, M. R., Futreal, P. A. (https://doi.org/10.1038/nature00766>
7. 2007) Phase II trial of sorafenib in patients with recurrent or metastatic squamous cell carcinoma of the head and neck or nasopharyngeal carcinoma. J. Clin. Oncol. 25, 3766-3773.
< , C., Siu, L. L., Winquist, E., Agulnik, M., Pond, G.. R., Chin, S. F., Francis, P., Cheiken, R., Elting, J., McNabola, A., Wilkie, D., Petrenciuc, O., Chen, E. X. (https://doi.org/10.1200/JCO.2006.10.2871>
8. 2005) Mutations of C-RAF are rare in human cancer because C-RAF has a low basal kinase activity compared with B-RAF. Cancer Res. 65, 9719-9726.
< , V., Garnett, M., Mason, C., Marais, R. (https://doi.org/10.1158/0008-5472.CAN-05-1683>
9. 2003) Effects of raf kinase inhibitor protein expression on suppression of prostate cancer metastasis. J. Natl. Cancer Inst. 95, 878-889.
< , Z., Smith, P. C., Zhang, L., Rubin, M. A., Dunn, R. L., Yao, Z., Keller, E. T. (https://doi.org/10.1093/jnci/95.12.878>
10. 2004) Guilty as charged: B-RAF is a human oncogene. Cancer Cell 6, 313-319.
< , M. J., Marais, R. (https://doi.org/10.1016/j.ccr.2004.09.022>
11. 2005) Frequent deletion and down-regulation of ING4, a candidate tumor suppressor gene at 12p13, in head and neck squamous cell carcinomas. Gene 356, 109-117.
< , M., Nagatsuka, H., Demircan, K., Gunduz, E., Cengiz, B., Ouchida, M., Tsujigiwa, H., Yamachika, E., Fukushima, K., Beder, L., Hirohata, S., Ninomiya, Y., Nishizaki, K., Shimizu, K., Nagai, N. (https://doi.org/10.1016/j.gene.2005.02.014>
12. 2008) Downregulation of ING3 mRNA expression predicts poor prognosis in head and neck cancer. Cancer Sci. 99, 531-538.
< , M., Beder, L. B., Gunduz, E., Nagatsuka, H., Fukushima, K., Pehlivan, D., Cetin, E., Yamanaka, N., Nishizaki, K., Shimizu, K., Nagai, N. (https://doi.org/10.1111/j.1349-7006.2007.00708.x>
13. 1995) Detection of K-ras mutations in DNAs isolated from feces of patients with colorectal tumors by mutant-allele-specific amplification (MASA). Oncogene 10, 1441-1445.
, Y., Takeda, S., Ichii, S., Koizumi, K., Maruyama, M., Fujii, A., Ohta, H., Nakajima, T., Okuda, M., Baba, S. (
14. 2007) RAS/RAF pathway activation in gliomas: the result of copy number gains rather than activating mutations. Acta Neuropathol. 114, 121-133.
< , J., van den Broecke, C., Gijsen, S., Boots-Sprenger, S., Wesseling, P. (https://doi.org/10.1007/s00401-007-0239-0>
15. 1995) Mutations, expression and genomic instability of the H-ras proto-oncogene in squamous cell carcinomas of the head and neck. Br. J. Cancer 72, 123-128.
< , H., Spandidos, D. A., Jones, A. S., Vaughan, E. D., Field, J. K. (https://doi.org/10.1038/bjc.1995.287>
16. 2006) Gefitinib (ZD1839, Iressa) as palliative treatment in recurrent or metastatic head and neck cancer. Br. J. Cancer 94, 631-636.
< , A. M., A’Hern, R. P., D’Ambrosio, C., Tanay, M., Syrigos, K. N., Rogers, S. J., Box, C., Eccles, S. A., Nutting, C. M., Harrington, K. J. (https://doi.org/10.1038/sj.bjc.6602999>
17. 1996) Control of the ERK MAP kinase cascade by Ras and Raf. Cancer Surv. 27, 101-125.
, R., Marshall, C. J. (
18. 2006) Mutational analysis of K-ras and Ras protein expression in larynx squamous cell carcinoma. J. Exp. Clin. Cancer Res. 25, 73-78.
R, L. M., Garcia-Cuellar, C. M., Herrera González, N. E., Suchil, B. L., Pérez-Cárdenas, E., Sácnchez-Pérez, Y., Suárez-Roa, M. L., Meneses, A. (
19. 1995) Treatment of cancer of the head and neck. CA Cancer J. Clin. 45, 352-368.
< , J. P., Lydiatt, W. (https://doi.org/10.3322/canjclin.45.6.352>
20. 2003) Mutations of the B-RAF gene in squamous cell carcinoma of the head and neck. Oncogene 22, 4757-4759.
< , A., Langhanki, L., Sommerer, F., Markwarth, A., Wittekind, C., Tannapfel, A. (https://doi.org/10.1038/sj.onc.1206705>
21. 2004) V599EB-RAF is an oncogene in melanocytes. Cancer Res. 64, 2338-2342.
< , C., Ogilvie, L., Hedley, D., Karasarides, M., Martin, J., Niculescu-Duvaz, D., Springer, C. J., Marais, R. (https://doi.org/10.1158/0008-5472.CAN-03-3433>
22. 2003) High prevalence of B-RAF gene mutation in papillary thyroid carcinomas and thyroid tumor cell lines. Cancer Res. 63, 4561-4567.
, X., Quiros, R. M., Gattuso, P., Ain, K. B., Prinz, R .A. (
23. 1994) Ras mutations and expression in head and neck squamous cell carcinomas. Laryngoscope 104, 1337-1347.
< , W. G., Shores, C., Witsell, D. L., Weissler, M. C., Fidler, M. E., Gilmer, T. M. (https://doi.org/10.1288/00005537-199411000-00005>
24. 2006) Two transforming C-RAF germ-line mutations identified in patients with therapy-related acute myeloid leukemia. Cancer Res. 66, 3401-3408.
< , A., Staber, P. B., Delavar, A., Bodner, C., Hiden, K., Fischereder, K., Janakiraman, M., Linkesch, W., Auner, H. W., Emberger, W., Windpassinger, C., Schimek, M. G., Hoefler. G., Troppmair, J., Sill, H. (https://doi.org/10.1158/0008-5472.CAN-05-0115>